Join to view full profile
3601 The Vanderbilt ClinicNashville, TN 37232
Phone+1 615-936-2000
Dr. Ferrell is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2015- Vanderbilt University Medical CenterResidency, Internal Medicine, 2009 - 2011
University of North Carolina at Chapel Hill School of MedicineClass of 2009
Certifications & Licensure
TN State Medical License 2011 - 2028
American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- TET2 loss enhances early response to inflammation in primitive and committed myeloid cells.Matthew T Jenkins, Rebecca Dubin, Kirsten M Dickerson, Phoebe Nguyen, Jing Wang
Experimental Hematology. 2026-05-01 - A 30-gene classifier distinguishes low-risk MDS HSPCs from healthy HSPCs.Pawan Bhat, Joseph C Van Amburg, Chad R Potts, Thomas J Gracie, Justin A Cartailler
Experimental Hematology. 2025-12-01 - 8 citationsGermline genetics, disease, and exposure to medication influence longitudinal dynamics of clonal hematopoiesis.Taralynn Mack, Yash Pershad, Caitlyn Vlasschaert, Cosmin A Bejan, Jonathan Brett Heimlich
Haematologica. 2025-04-01
Lectures
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- IDH2 Mutations Induce Altered STAT Signaling and Cytokine Responses Which Are Restored By Enasidenib2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Potential Treatment Eyed for Abnormal Blood Cell DisorderNovember 25th, 2024
Grant Support
- Dissecting Clonal Evolution of Myeloid MalignanciesVETERANS HEALTH ADMINISTRATION2024–2027
- Delineating Drivers of Inflammation and Progression in Clonal HematopoiesisVANDERBILT UNIVERSITY MEDICAL CENTER2023–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
